List of Excipients in Branded Drug NEVIRAPINE

Generic Drugs Containing NEVIRAPINE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	nevirapine	0378-4050	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	nevirapine	0378-4050	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	nevirapine	0378-4050	MICROCRYSTALLINE CELLULOSE 101
Mylan Pharmaceuticals Inc	nevirapine	0378-4050	MICROCRYSTALLINE CELLULOSE 102
Mylan Pharmaceuticals Inc	nevirapine	0378-4050	POVIDONE K30

What are the Most Frequently-Used Excipients in NEVIRAPINE?

# Of NDCs	Excipient
1	CARBOMER HOMOPOLYMER TYPE A
1	CARBOMER HOMOPOLYMER TYPE B
11	CELLULOSE, MICROCRYSTALLINE
2	COLLOIDAL SILICON DIOXIDE
3	CROSCARMELLOSE SODIUM

Excipient Strategy and Commercial Opportunities for NVP (Nevirapine)

Last updated: March 6, 2026

What are the key excipient considerations for NVP formulation development?

Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used in HIV treatment. Its formulation requires specific excipient strategies to optimize bioavailability, stability, and patient compliance.

Formulation composition and stability

• NVP is poorly soluble, classified as BCS Class II.
• Common excipients include surfactants (e.g., poloxamers) to enhance solubility.
• Solubilizers and pH adjusters are used to improve stability and bioavailability.
• Excipients like microcrystalline cellulose and lactose serve as fillers and diluents.

Regulatory considerations

• Compatibility of excipients with NVP is critical to prevent degradation.
• Excipients must be recognized as safe (GRAS) and compliant with FDA or EMA guidelines.
• Use of novel excipients is limited due to safety data requirements.

Delivery format options

• Tablets: require disintegrants, binders, and lubricants tailored for immediate or controlled release.
• Suspensions: need surfactants and suspending agents to maintain homogeneity.
• Long-acting formulations: incorporate polymers or biodegradable matrices as excipients.

What commercial opportunities exist through excipient innovation?

Enhanced bioavailability formulations

• Developing solubility-enhancing excipients offers opportunities to reduce dose size.
• Lipid-based formulations can improve absorption and tissue penetration.
• These modifications can differentiate products in a competitive market.

Patient-centric formulations

• Fasting and food effect considerations drive the need for excipients that stabilize NVP in various environments.
• Developing formulations with improved taste masking can increase adherence.

Fixed-dose combination (FDC) products

• Excipient compatibility with NVP and other antiretrovirals is critical.
• Combining excipients to co-formulate NVP with other drugs reduces pill burden.
• Market demand for once-daily, co-formulated therapies enhances commercial value.

Biosimilar and generic opportunities

• Streamlined excipient choices enable faster approval pathways.
• Cost-effective excipient use supports lower pricing strategies.

Novel delivery systems

• Nanoparticles, micelles, or implantable devices expanding excipient use create premium products.
• These innovations target niche markets like pediatric or resistant HIV infections.

Regulatory and market dynamics

Aspect	Detail
Regulatory pathways	ANDA (abbreviated new drug application) for generics; NDA (new drug application) for innovator products
Market size	Global HIV therapeutics market valued at $21.9 billion (2022), projected to grow at 4.2% CAGR through 2030 [1]
Key competitors	GSK, ViiV Healthcare, Teva, Mylan
Patent landscape	Patent expirations for NVP-based formulations have increased generic entry opportunities

Strategic considerations

• Focus on excipients that improve NVP's solubility and stability to meet unmet need.
• Invest in formulation platforms that enable flexible dosing and improved compliance.
• Leverage excipient innovations to extend patent life or enter assembly lines with faster approval.

Key Takeaways

• Excipient strategies for NVP focus on solubility enhancement, stability, and patient adherence.
• Innovations in delivery formats, such as lipid-based or nanoparticle systems, present commercial growth avenues.
• Co-formulation with other antiretrovirals requires compatible excipients to minimize manufacturing complexity.
• Regulatory pathways favor excipient choices that are safe, well-characterized, and compliant.
• The expanding HIV market and patent expirations create opportunities for generics and advanced formulations.

FAQs

1. How does excipient selection impact NVP bioavailability?
Excipient choices influence NVP dissolution and intestinal absorption. Surfactants and solubilizers enhance its poor water solubility, improving bioavailability.

2. What challenges exist in formulating NVP?
NVP's low solubility and stability issues require careful excipient selection to prevent degradation and ensure consistent dosing.

3. Are there proprietary excipient technologies beneficial for NVP?
Yes. Lipid-based excipients, self-emulsifying systems, and biodegradable polymers can improve delivery but require regulatory clearance.

4. How does excipient compatibility affect patent prospects?
Selecting novel or optimized excipients can extend patent life by creating differentiated formulations that are less prone to generic competition.

5. What market segments are most receptive to NVP formulation innovations?
Developing countries with high HIV prevalence and pediatric populations benefit from formulations that prioritize stability, taste, and ease of administration.

---

References

[1] MarketsandMarkets. (2022). HIV Therapeutics Market Size, Share & Trends. Available at: https://www.marketsandmarkets.com/